US-based global biopharmaceutical company PTC Therapeutics, Inc. (NASDAQ: PTCT) announced on Monday that the US FDA has set a target action date of 29 July 2025, for the review of its New Drug Application (NDA) for sepiapterin.
The application seeks approval for the treatment of paediatric and adult patients with phenylketonuria (PKU) across all age groups and disease subtypes. The NDA includes data from the Phase 3 APHENITY trial, recently published in The Lancet, as well as ongoing data from the APHENITY open-label extension study.
Sepiapterin, an oral synthetic compound, has a dual mechanism that enhances the activity of the phenylalanine hydroxylase (PAH) enzyme. This mechanism helps reduce blood phenylalanine levels, offering potential treatment for a broad range of PKU patients. Results from the Phe tolerance assessment show that around 60% of subjects can increase protein intake while maintaining safe phenylalanine levels. PKU is a rare genetic metabolic disorder affecting brain function, with approximately 58,000 individuals affected worldwide.
Sanofi commits USD18m to boost diversity in clinical studies
GSK PLC announces acceptance of NDA for gepotidacin by US FDA
Anixa Biosciences administers second dose of CAR-T therapy to individual patient
Saniona reaches milestone in Boehringer Ingelheim partnership
Lipella granted patent for innovative drug delivery technology
SystImmune receives FDA clearance for Phase 1 trial of novel AML therapy
PTC Therapeutics' sepiapterin receives US FDA target regulatory action date
PharmAbcine's PMC-403 Phase one clinical trial single ascending dose cohort receives safety approval
RedHill Biopharma's opaganib selected for Ebola treatment development by BARDA
Exelixis and Merck collaborate on clinical development of zanzalintinib
BD launches automated reagent kit to streamline single-cell discovery studies
Transgene's Phase II trial of TG4001 falls short of primary objective
Lundbeck agrees to acquire Longboard Pharmaceuticals to enhance neuroscience pipeline